12 Minutes in Conversation with Nick Skaer, CEO of Orthox
Join OIC Partner James Mallinson for Episode 5 of the OIC Conversations Series.
Orthox is developing tissue regenerative knee implants to help patients with cartilage damage return to a fully active, pain free life. Orthox’s FibroFix™ technology is based on a protein produced by the silk moth, Bombyx mori, which is moulded into a structure that supports and promotes tissue regeneration in the joint.
- 00:28 – Tell us a little about yourself and how you founded Orthox
- 01:36 – What was the problem you identified and how is Orthox trying to solve it?
- 02:42 – Why is silk such a compelling material for biomedical applications?
- 03:41 – How large is the opportunity for Orthox, both in the UK and globally?
- 04:49 – How is the Company being funded?
- 05:45 – What are the key goals for the business in the next 12 months?
- 06:28 – How do you plan to bring Orthox’s products to market and sell them?
- 07:27 – What are the effects of COVID-19 on the business and what are you doing to mitigate these?
- 09:40 – What are the advantages of being a spinout from the University of Oxford?
- 10:28 – What is the long term vision for Orthox?
Important notice: This communication is for information purposes only. Reliance on the information in this communication, for the purpose of engaging in any investment activity, may expose an individual to a risk of losing all of the funds invested. The information disclosed in this communication does not constitute, or should be considered as, an offer to buy or sell or solicitation of an offer to buy or sell any security or share.